MannKind Corporation (MNKD)

MannKind's stock price has declined by 37.14% in the past six months. Recent events include a Q1 2026 earnings report showing a 15% year-over-year revenue increase but a non-GAAP net loss, upcoming PDUFA dates for Afrezza and FUROSCIX, a $5 million payment from United Therapeutics to accelerate ralinepag DPI development, and the acquisition of scPharmaceuticals in October 2025.

Demand for MannKind's products, particularly FUROSCIX, can be affected by seasonality due to annual deductible resets, which tend to reduce early-year fills. MannKind has a seasonality score of -20, indicating some degree of demand seasonality.

MannKind Corporation is a biopharmaceutical company focused on transforming chronic disease care through patient-centric therapies, primarily for cardiometabolic and orphan lung diseases. Its core business involves the discovery, development, and commercialization of innovative therapeutic products, utilizing its Technosphere® platform for inhaled drug delivery. Major products include Afrezza® for diabetes, FUROSCIX® for fluid overload, V-Go® insulin delivery patch, and Tyvaso DPI® for pulmonary hypertension. The pipeline includes MNKD-101 for NTM lung disease, Nintedanib DPI for IPF, and Bumetanide DPI for edema, along with collaborations with United Therapeutics.

MannKind Corporation is headquartered in Danbury, Connecticut, which includes its manufacturing and R&D site. It also has a West Coast office in Westlake Village, California, and Boston locations in Bedford and Burlington, Massachusetts. The company employs field sales and medical representatives across the United States.

MannKind Corporation emphasizes a patient-centric approach, aiming to transform chronic disease care through innovative solutions. The acquisition of scPharmaceuticals in late 2025 was viewed positively, and the recent market reaction to the Q1 2026 earnings report suggests investor confidence in the company's long-term growth potential.

MannKind Corporation has significant institutional ownership, with 264 institutional owners holding 58.54% of the company's stock. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, and State Street Corp. Alfred E. Mann, the founder, is the largest individual shareholder, owning 91.53% of the company. Insider ownership stands at 4.68%.